Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Factors associated with hospital admission and adverse outcome for COVID-19: role of social factors and medical care

Beaumont et al., Infectious Diseases Now, doi:10.1016/j.idnow.2022.02.001
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Death/intubation 14% Improvement Relative Risk HCQ for COVID-19  Beaumont et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 296 patients in France Lower death/intubation with HCQ (not stat. sig., p=0.55) c19hcq.org Beaumont et al., Infectious Diseases Now, Feb 2022 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
Retrospective 296 hospitalized patients in France, showing no significant difference with HCQ treatment.
risk of death/intubation, 14.1% lower, HR 0.86, p = 0.55, treatment 7 of 38 (18.4%), control 88 of 258 (34.1%), NNT 6.4, adjusted per study, odds ratio converted to relative risk, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Beaumont et al., 13 Feb 2022, retrospective, France, peer-reviewed, 22 authors, average treatment delay 6.0 days.
This PaperHCQAll
Factors associated with hospital admission and adverse outcome for COVID-19: Role of social factors and medical care
A-L Beaumont, D Vignes, R Sterpu, G Bussone, I Kansau, C Pignon, R Ben Ismail, M Favier, J-L Molitor, D Braham, R Fior, S Roy, M Mion, L Meyer, M Andronikof, C Damoisel, P Chagué, J-C Aurégan, N Bourgeois-Nicolaos, C Guillet-Caruba, J-P Téglas, Sophie Abgrall
Infectious Diseases Now, doi:10.1016/j.idnow.2022.02.001
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
Anand, Montez-Rath, Han, Bozeman, Kerschmann et al., Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study, Lancet, doi:10.1016/S0140-6736(20)32009-2
Bartoletti, Giannella, Scudeller, Tedeschi, Rinaldi et al., Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study), Clin Microbiol Infect, doi:10.1016/j.cmi.2020.08.003
Borges Do Nascimento, Groote, Mathúna, Abdulazeem, Henderson et al., Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-CoV-2) infection in humans: A systematic review and series of meta-analyses, PLoS One, doi:10.1371/journal.pone.0239235
Czernichow, Obesity doubles mortality in patients hospitalized for SARS-CoV-2 in Paris hospitals, France: a cohort study on 5795 patients, Obesity, doi:10.1002/oby.23014
Docherty, Harrison, Green, Hardwick, Pius et al., Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study, BMJ, doi:10.1136/bmj.m1985
Fadel, Early Short Course Corticosteroids in Hospitalized Patients with COVID-19, Clin Infect Dis, doi:10.1093/cid/ciaa601
Fiolet, Guihur, Rebeaud, Mulot, Peiffer-Smadja et al., Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.08.022
Gabarre, Dumas, Dupont, Darmon, Azoulay et al., Acute kidney injury in critically ill patients with COVID-19, Intensive Care Med, doi:10.1007/s00134-020-06153-9
Goutte, Péran, Porcher, The role of economic structural factors in determining pandemic mortality rates: Evidence from the COVID-19 outbreak in France, Res Int Bus Financ, doi:10.1016/j.ribaf.2020.101281
Horby, Lim, Emberson, Group, Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, N Engl J Med, doi:10.1056/nejmoa2021436
Jia, Hirsch, Hazzan, Wanchoo, Shah et al., Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury, Am J Kidney Dis, doi:10.1053/j.ajkd.2020.09.002
Ko, Danielson, Town, Derado, Greenlund et al., Risk factors for COVID-19-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system, Clin Infect Dis, doi:10.1093/cid/ciaa1419
Lewis, Friedrichs, Wagstaff, Sage, Lacross et al., Disparities in COVID-19 Incidence, Hospitalizations, and Testing, by Area-Level Deprivation -Utah, MMWR
Malik, Patel, Mehta, Patel, Kelkar et al., Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis, BMJ Evidence-Based Med, doi:10.1136/bmjebm-2020-111536
Mueller, Tamura, Crowley, Grado, Haider et al., Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients, Cell Reports Med, doi:10.1016/j.xcrm.2020.100144
Patel, Hiam, Sowemimo, Devakumar, Mckee, Ethnicity and covid-19, BMJ, doi:10.1136/bmj.m2282
Petrilli, Jones, Yang, Rajagopalan, Donnell et al., Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study, BMJ, doi:10.1136/bmj.m1966
Raifman, Raifman, Disparities in the Population at Risk of Severe Illness From COVID-19 by Race/Ethnicity and Income, Am J Prev Med, doi:10.1016/j.amepre.2020.04.003
Rki, Destatis, Social inequalities and COVID-19, J Heal Monit
Shang, Zhao, Hu, Du, Cao, On the use of corticosteroids for 2019-nCoV pneumonia, Lancet, doi:10.1016/S0140-6736(20)30361-5
Soares R De, Mattos, Raposo, Risk Factors for Hospitalization and Mortality due to COVID-19 in Espírito Santo State, Brazil, Am J Trop Med Hyg, doi:10.4269/ajtmh.20-0483
Sterne, Murthy, Diaz, Slutsky, Villar et al., Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis, JAMA -J Am Med Assoc, doi:10.1001/jama.2020.17023
Toussie, Voutsinas, Finkelstein, Cedillo, Manna et al., Clinical and chest radiography features determine patient outcomes in young and middle-aged adults with COVID-19, Radiology, doi:10.1148/radiol.2020201754
Villar, Confalonieri, Pastores, Meduri, Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019, Crit Care Explor, doi:10.1097/cce.0000000000000111
Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors associated with COVID-19-related death using OpenSAFELY, Nature, doi:10.1038/s41586-020-2521-4
Yehia, Winegar, Fogel, Fakih, Ottenbacher et al., Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.18039
{ 'indexed': {'date-parts': [[2022, 2, 13]], 'date-time': '2022-02-13T14:40:39Z', 'timestamp': 1644763239575}, 'reference-count': 0, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 2, 1]], 'date-time': '2022-02-01T00:00:00Z', 'timestamp': 1643673600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['Infectious Diseases Now'], 'published-print': {'date-parts': [[2022, 2]]}, 'DOI': '10.1016/j.idnow.2022.02.001', 'type': 'journal-article', 'created': {'date-parts': [[2022, 2, 13]], 'date-time': '2022-02-13T14:24:59Z', 'timestamp': 1644762299000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'Factors associated with hospital admission and adverse outcome for COVID-19: role of social ' 'factors and medical care'], 'prefix': '10.1016', 'author': [ {'given': 'A-L', 'family': 'Beaumont', 'sequence': 'first', 'affiliation': []}, {'given': 'D', 'family': 'Vignes', 'sequence': 'additional', 'affiliation': []}, {'given': 'R', 'family': 'Sterpu', 'sequence': 'additional', 'affiliation': []}, {'given': 'G', 'family': 'Bussone', 'sequence': 'additional', 'affiliation': []}, {'given': 'I', 'family': 'Kansau', 'sequence': 'additional', 'affiliation': []}, {'given': 'C', 'family': 'Pignon', 'sequence': 'additional', 'affiliation': []}, {'given': 'R', 'family': 'Ben Ismail', 'sequence': 'additional', 'affiliation': []}, {'given': 'M', 'family': 'Favier', 'sequence': 'additional', 'affiliation': []}, {'given': 'J-L', 'family': 'Molitor', 'sequence': 'additional', 'affiliation': []}, {'given': 'D', 'family': 'Braham', 'sequence': 'additional', 'affiliation': []}, {'given': 'R', 'family': 'Fior', 'sequence': 'additional', 'affiliation': []}, {'given': 'S', 'family': 'Roy', 'sequence': 'additional', 'affiliation': []}, {'given': 'M', 'family': 'Mion', 'sequence': 'additional', 'affiliation': []}, {'given': 'L', 'family': 'Meyer', 'sequence': 'additional', 'affiliation': []}, {'given': 'M', 'family': 'Andronikof', 'sequence': 'additional', 'affiliation': []}, {'given': 'C', 'family': 'Damoisel', 'sequence': 'additional', 'affiliation': []}, {'given': 'P', 'family': 'Chagué', 'sequence': 'additional', 'affiliation': []}, {'given': 'J-C', 'family': 'Aurégan', 'sequence': 'additional', 'affiliation': []}, {'given': 'N', 'family': 'Bourgeois-Nicolaos', 'sequence': 'additional', 'affiliation': []}, {'given': 'C', 'family': 'Guillet-Caruba', 'sequence': 'additional', 'affiliation': []}, {'given': 'J-P', 'family': 'Téglas', 'sequence': 'additional', 'affiliation': []}, {'given': 'S', 'family': 'Abgrall', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'container-title': ['Infectious Diseases Now'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S266699192200032X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S266699192200032X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 2, 13]], 'date-time': '2022-02-13T14:24:59Z', 'timestamp': 1644762299000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 2]]}, 'references-count': 0, 'alternative-id': ['S266699192200032X'], 'URL': 'http://dx.doi.org/10.1016/j.idnow.2022.02.001', 'relation': {}, 'ISSN': ['2666-9919'], 'issn-type': [{'value': '2666-9919', 'type': 'print'}], 'subject': ['Infectious Diseases'], 'published': {'date-parts': [[2022, 2]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit